Loading...

Viola Weijia Zhu

Title(s)Assistant Health Sciences Professor, Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC. J Thorac Oncol. 2020 Jul; 15(7):e124-e127. Zhu VW, Madison R, Schrock AB, Ignatius Ou SH. PMID: 32593453.
      View in: PubMed   Mentions:
    2. US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2020 Jun 26. Papadopoulos KP, Borazanci E, Shaw AT, Katayama R, Shimizu Y, Zhu VW, Sun TY, Wakelee HA, Madison R, Schrock AB, Senaldi G, Nakao N, Hanzawa H, Masaya T, Isoyama T, Nakamaru K, Deng C, Li M, Fran F, Zhao Q, Gao Y, Seto T, Janne PA, Ou SI. PMID: 32591465.
      View in: PubMed   Mentions:    Fields:    
    3. Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. J Thorac Oncol. 2020 Jun 12. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. PMID: 32540409.
      View in: PubMed   Mentions:    Fields:    
    4. An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC. J Thorac Oncol. 2020 Apr 28. Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YLE, Ock CY, Tchekmedyian N, Ignatius Ou SH, Syn NL, Reungwetwattana T, Lin CC, Soo RA. PMID: 32360579.
      View in: PubMed   Mentions:    Fields:    
    5. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020 Mar 18. Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, Xia B, Zhu VW, Nagasaka M, Yang Y, Li Y, Qiu W, Ying J, Ou SI, Wang Y. PMID: 32336530.
      View in: PubMed   Mentions:    Fields:    
    6. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. Lung Cancer (Auckl). 2020; 11:13-18. Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. PMID: 32021525.
      View in: PubMed   Mentions:
    7. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends Cancer. 2019 11; 5(11):677-692. Zhu VW, Klempner SJ, Ou SI. PMID: 31735287.
      View in: PubMed   Mentions:    Fields:    
    8. Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2020 Feb; 15(2):258-265. Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT. PMID: 31669591.
      View in: PubMed   Mentions:    Fields:    
    9. Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]. Lung Cancer. 2019 Dec; 138:141. Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM. PMID: 31447233.
      View in: PubMed   Mentions: 2     Fields:    
    10. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 08 01; 30(8):1321-1328. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. PMID: 31125062.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    11. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 07; 133:96-102. Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. PMID: 31200835.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification. Lung Cancer (Auckl). 2019; 10:21-26. Zhu VW, Schrock AB, Ali SM, Ou SI. PMID: 30881166.
      View in: PubMed   Mentions:
    13. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer. 2019 04; 130:201-207. Ou SI, Zhu VW. PMID: 30885345.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer (Auckl). 2018; 9:111-116. Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI. PMID: 30519133.
      View in: PubMed   Mentions:
    15. Pacific Rim redux: lorlatinib, the ultimate Jaeger? Ann Transl Med. 2018 Nov; 6(Suppl 1):S40. Zhu VW, Ou SI. PMID: 30613615.
      View in: PubMed   Mentions:
    16. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. PMID: 30257958.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    17. Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis. Clin Lung Cancer. 2019 01; 20(1):e77-e80. Zhu VW, Lu Y, Ou SI. PMID: 30318176.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018 10; 8(10):1227-1236. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. PMID: 30093503.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-a N848?K mutation. Lung Cancer. 2018 10; 124:86-89. Klempner SJ, Gowen K, Lee TK, Zhu VW, Schrock AB, Miller VA, Ali SM, Ou SI. PMID: 30268485.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018; 2018. Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. PMID: 30215037.
      View in: PubMed   Mentions:
    21. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018 10; 13(10):1530-1538. Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ. PMID: 29935304.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2018 09; 13(9):1312-1323. Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI. PMID: 29883838.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    23. The allure of 'ALUR'. Ann Oncol. 2018 06 01; 29(6):1344-1346. Nagasaka M, Zhu VW, Ou SI. PMID: 29688274.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:978-997. Ou SI, Nagasaka M, Zhu VW. PMID: 30231331.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 04 20; 36(12):1199-1206. Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. PMID: 29373100.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    26. METex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure? J Thorac Oncol. 2017 08; 12(8):1180-1182. Zhu VW, Ou SI. PMID: 28748813.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer. 2017 08; 110:32-34. Zhu VW, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SI. PMID: 28676215.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    28. A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer). Clin Neurol Neurosurg. 2017 Jul; 158:46-48. Zhu VW, Hinduja S, Knezevich SR, Silveira WR, DeLozier CD. PMID: 28460341.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer. 2017 06; 108:228-231. Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM. PMID: 28625641.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    30. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf. 2017 Apr; 16(4):509-514. Zhu V, Ou SH. PMID: 28276856.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    31. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer. 2017 04; 106:110-114. Ou SI, Lee TK, Young L, Fernandez-Rocha MY, Pavlick D, Schrock AB, Zhu VW, Milliken J, Ali SM, Gitlitz BJ. PMID: 28285684.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    32. ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res. 2016 Dec; 5(6):660-664. Zhu VW, Ou SI. PMID: 28149759.
      View in: PubMed   Mentions:
    33. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2017 01; 12(1):137-140. Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM. PMID: 27666659.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    Viola's Networks
    Concepts (93)
    Derived automatically from this person's publications.
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _